NEW ORLEANS Developmental drugs would preserve muscle mass and increase fat loss when used in combination with glucagon-like peptide 1 (GLP-1) receptor agonists taken for weight loss. As medications such as semaglutide (Wegovy) and the glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 dual agonist tirzepatide (Zepbound) are producing unprecedented rates of weight loss in increasing numbers of people,…